Certara®, a global leader in biosimulation, today announced that it has appointed Nicolette D. Sherman to the position of Chief Human Resources Officer (CHRO). Sherman joins Certara with extensive experience in the biopharmaceutical industry, leading HR strategy and implementing programs to drive business impact.
“We are pleased to have Nicolette join Certara as we continue to grow our high-performing team and capabilities worldwide,” said William F. Feehery, chief executive officer. “She has a proven track record of achieving organizational results through advancing corporate values and building competencies. We look forward to her contributions to Certara.”
Most recently, Sherman was CHRO at Oyster Point Pharma, where she developed the human resources function of the newly public biotech company, establishing the infrastructure needed to support commercialization. Prior to that, she served in multiple roles at Sanofi for 12 years, including Vice President of North American Human Resources Operations and Vice President of Global Leadership Development. Sherman was responsible for leading a large team of HR professionals, providing support across all areas of the employment cycle for the 5 diverse business units and all functional areas in North America.
“I am honored to join Certara and look forward to contributing to its important work in transforming drug development and bringing new therapies to market,” said Ms. Sherman. “Certara has impressive breadth and depth of scientific and regulatory expertise, and I am excited to play a role in continuing to build upon the world-class team.”
About Certara
Certara accelerates medicines using biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.
Investor Relations Contact:
David Deuchler
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Ariane Lovell
Finn Partners
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$8.17 |
| Daily Change: | -0.16 -1.92 |
| Daily Volume: | 1,558,315 |
| Market Cap: | US$1.300B |
November 06, 2025 October 30, 2025 September 04, 2025 August 06, 2025 August 04, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
